Prof. Avner Rotman PhD – Chairman of the Board
Professor Avner Rotman is Chairman of the Board at BiondVax. After an academic career at the Weizmann Institute of Science, Prof. Rotman founded Bio-Dar, a company specializing in controlled release Pharmaceuticals, Health and Nutrition, where he served as President and CEO for 15 years until the company was sold to the Machteshim-Agan/Lycored Group. In 2000 he founded Rodar Technologies, a company focused on technology transfer in the high tech industry, where he currently serves as CEO and Chairman of the Board. Prof. Rotman is a member of the steering committee of the Israeli Biotechnology Organization, and is extensively involved with Biotechnology incubators in Israel and with the Life Science business community. He is Founder and Chairman of the Foundation of Cardiovascular Research in Israel. Prof. Rotman received his PhD from the Weizmann Institute of Science, Israel.
Dr. Ron Babecoff, DVM – Founder, President and CEO
Dr. Ron Babecoff co-founded BiondVax in 2003, and has led the Company as its President and CEO since its inception. Prior to the founding of BiondVax, Dr. Babecoff had worked for 10 years in marketing and business development in the pharmaceutical industry. In his last position as Marketing Manager at Omrix Biopharmaceuticals Ltd., Dr. Babecoff was responsible for marketing, sales training, public relations, and new product development. Some significant projects that Dr. Babecoff was then involved in include identifying West Nile Fever treatments and building cooperation with the US NIH, and forming alliances with leading international pharmaceutical companies. Dr. Babecoff holds a DVM degree from the University of Liège (ULg), Belgium and a Master of Entrepreneurship and Innovation (MEI) from the Swinburne University of Technology of Melbourne, Australia.
Dr. George Lowell, MD – Director
Dr. George Lowell joined the Company in 2008. Dr. Lowell is the former Chief Scientific Officer of BioDefense at GlaxoSmithkline Biologicals and, prior to that, the CSO of ID Biomedical (subsequently acquired by GSK). He served as a Doctor (Consultant in Pediatric Infectious Diseases) and researcher at the Walter Reed General Hospital (US Army hospital) for 20 years. He subsequently founded and managed Intellivax, a vaccines R&D company that was acquired by ID Biomedical. Dr. Lowell has held a number of academic posts, including Visiting Scientist at the Weizmann Institute of Science (Israel) as well as Visiting Professor, Hebrew University-Hadassah Medical Center (Israel). Dr. Lowell is a Colonel (retired) in the US Army.
Mr. Jack Rosen – Director
Mr. Jack Rosen, currently President of the American Jewish Congress and Chairman of the American Council for World Jewry, Inc., is the founder and Chief Executive Officer of the successful New York real estate firm, Rosen Partners LLC. Since founding Rosen Partners LLC almost 30 years ago, Mr Rosen has grown his company to become a leader in creating residential, commercial and hotel developments worldwide. In addition, Mr. Rosen currently serves as a Board Director at Fusion Telecommunications International, Inc., New York, NY. His wide array of business interests includes ventures operating throughout the United States, Europe and Asia in healthcare, cosmetics, telecommunications and security. Notably, a long-time advisor to US presidents from both parties, Mr Rosen has received various appointments including membership of the NASA Advisory Council.
Mrs. Michal Marom Brikman – Director
Mrs. Michal Marom Brikman served as Financial Officer of Linkury Technology International Group and as a Professional Assistant to the president of the Institute of CPA in Israel. She serves as a director in the following firms: Union Bank, Spectronix , Naaman Vardinon, Biomedix incubator, ADO group, Arko holdings, Algomizer, and Dan Transportation. Mrs. Marom Brikman holds a MA in finance from the Baruch College of Management, NYU and a BA from the College of Management Academic Studies.
Dr. Ruth Ben Yakar, PhD – Director
Dr. Ruth Ben Yakar has over 22 years of experience in the biomedical field, including 15 years of management in the biotech industry, leading diverse corporate, business, operational, financial, clinical development, and research activities. Dr. Ben Yakar serves as the CEO of BioSight , a clinical-phase biotech company, a Director at SHL Telemedicine and Cellect Biomed, a business consultant to several biomed companies, and a guest lecturer at Lahav, the Recannati Business School of Tel-Aviv University. She formerly served as the CEO of the biotech companies Procognia and Thrombotech, as a Director at IATI, as the Chief Business Officer of YEDA, the technology transfer company of the Weizmann Institute of Science, and as a Vice President in several Biotech companies. Dr. Ben Yakar holds a PhD Cum Laude from the Weizmann Institute of Science.
Mr. Ori Mor – Director
Mr. Ori Mor has over 20 years of experience as a senior financial manager in medical technology and money managers companies. He is Founder and CEO of Mor Langerman Ltd., a consulting firm specializing in life sciences. He currently serves as director at several public companies, including at Excellence Nessuah pension funds and serves as Chairman of Mordechai Aviv. Mr. Mor recently served as CFO of several life science companies including 5 years as CFO at the public medical device company MCS. Mr. Mor has also served as Chief Investment Officer (CIO) for an institutional investors company. He holds an MA (Economics) from Ben-Gurion University of the Negev.
Mr. Isaac Devash – Director
Mr. Isaac Devash is an entrepreneur with over twenty years of experience in venture capital and private equity investments, and several years of experience as an investment banker specializing in mergers and acquisitions at Credit Suisse First Boston in New York, London, and Tokyo. Mr. Devash has established a number of private equity funds and assisted a variety of Israeli companies in their international development and a number of leading international investors in their investments in Israel. He was a member of the Goshen Committee for formulating the standards of corporate governance for Israeli public companies. As well, Mr. Devash founded and serves as the Chairman of both the Wharton and Harvard Business School alumni clubs. Mr. Devash holds a bachelor’s degree, summa cum laude, from the Wharton School of the University of Pennsylvania and an MBA from Harvard University.
Dr. Morris C. Laster, M.D.
Dr. Laster possesses over 25 years of experience in the Biomed industry, with expertise in identification, evaluation, finance and management of biomedical innovations in both public and private companies. Dr. Laster is a Venture Partner at OurCrowd, a world leading crowd funding platform, and is the CEO of Clil Medical Ltd., a biomedical consultancy company. He is also the CEO of Vital Spark Inc., a new company developing novel dual action cannabinoids licensed from the NIH. Previously, he served as the founding CEO and director of BioLineRx Ltd. (NASDAQ/TASE: BLRX) from 2003 to 2010. Dr. Laster is also one of the founders of Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), and served as a director in Kitov from 2010 to 2014. Dr. Laster holds an M.D. degree from SUNY Health Science Center At Brooklyn (SUNY HSCB) and B.S. in Biology, Magna Cum Laude, from State University of New York at Albany.